Left ventricular assist device explantation using a new double-patch technique†.
Heart failure
Left Ventricular Assist Device Explantation
Left Ventricular Assist Device weaning
Mechanical Circulatory Support
Journal
Interdisciplinary cardiovascular and thoracic surgery
ISSN: 2753-670X
Titre abrégé: Interdiscip Cardiovasc Thorac Surg
Pays: England
ID NLM: 9918540787006676
Informations de publication
Date de publication:
19 Jul 2023
19 Jul 2023
Historique:
received:
24
05
2023
revised:
14
06
2023
accepted:
23
07
2023
medline:
24
7
2023
pubmed:
24
7
2023
entrez:
24
7
2023
Statut:
ppublish
Résumé
There are several surgical approaches for explanting a left ventricular assist device (LVAD) after recovery of cardiac function. Thus, remaining ventricular assist device components may bear significant risks of infection or thrombosis. We hereby report our technique and two-center experience with explantation of LVADs using a new double-patch technique. From March 2019 to April 2021, five patients underwent LVAD explantation after myocardial recovery (HVAD, n = 2; HeartMate 3, n = 3). The mean patient age was 50.3 years (100% male); the mean time on the LVAD was 23.1 ± 20.8 months. The aetiology of the primary heart failure was dilated cardiomyopathy (n = 4) and myocarditis (n = 1).LVAD explantation was performed using a median sternotomy and cardiopulmonary bypass. The LVAD was stopped, and the outflow graft was clamped. The outflow graft was ligated and sutured close to the aortic anastomosis. The driveline was clipped and removed. Under induced fibrillation, the attachment of the LVAD was released from the apical cuff and the LVAD was removed. A round pericardial patch was fixed from the inner of the ventricle. This step sealed the apex of the heart. An additional Gore-Tex patch was continuously sutured epicardially over the suture ring. The 5 cases showed technically uncomplicated explantation of the LVADs. During the follow-up of a mean of 16.4 ± 16.9 months, we observed 100% survival. There were no bleeding complications or thromboembolic events during the follow-up period. LVAD explantation with the double-patch technique is feasible and safe. This technique allows discontinuation of anticoagulation. The 30-day survival was 100%. Further studies are needed to provide better evidence for LVAD explantation and long-term follow-up.
Identifiants
pubmed: 37486261
pii: 7229990
doi: 10.1093/icvts/ivad110
pmc: PMC10371393
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.
Références
N Engl J Med. 2009 Dec 03;361(23):2241-51
pubmed: 19920051
Ann Thorac Surg. 1999 Mar;67(3):723-30
pubmed: 10215217
N Engl J Med. 2007 Aug 30;357(9):885-96
pubmed: 17761592
ASAIO J. 2022 Jun 1;68(6):822-828
pubmed: 34560718
J Heart Lung Transplant. 2021 Dec;40(12):1560-1570
pubmed: 34479776
J Heart Lung Transplant. 2010 Jun;29(6):603-9
pubmed: 20202864
Eur J Cardiothorac Surg. 2021 Apr 29;59(4):855-862
pubmed: 33367693
J Clin Med. 2022 Apr 05;11(7):
pubmed: 35407630
Heart Lung Circ. 2018 Jul;27(7):853-855
pubmed: 28887110
J Heart Lung Transplant. 2010 Jun;29(6):672-9
pubmed: 20188595
J Am Coll Cardiol. 2016 Oct 4;68(14):1540-53
pubmed: 27687196
ASAIO J. 2020 Jan;66(1):17-22
pubmed: 30489294
Interact Cardiovasc Thorac Surg. 2022 Mar 31;34(4):683-690
pubmed: 34888681
J Am Coll Cardiol. 2011 Feb 8;57(6):641-52
pubmed: 21292124